Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, et al. J Thorac Oncol 2022;17:568-577.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, et al. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. J Thorac Oncol 2022;17:568-577.
PMID: 35026476